Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-Small Cell Lung Carcinoma
|
712 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.980 | 406 | 2005 | 2020 | ||||
Neoplasms
|
1644 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.987 | 150 | 2005 | 2020 | ||||
Malignant neoplasm of lung
|
1142 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.974 | 115 | 2005 | 2019 | ||||
Carcinoma of lung
|
1204 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.981 | 103 | 2005 | 2019 | ||||
Primary malignant neoplasm of lung
|
981 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.980 | 102 | 2005 | 2019 | ||||
Adenocarcinoma of lung (disorder)
|
563 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 45 | 2006 | 2020 | ||||
Adenocarcinoma
|
168 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 0.950 | 20 | 2006 | 2019 | ||||
Malignant Neoplasms
|
1641 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 20 | 2007 | 2020 | ||||
Primary malignant neoplasm
|
1374 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 16 | 2007 | 2020 | ||||
Small cell carcinoma of lung
|
125 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 15 | 2013 | 2019 | ||||
Metastatic malignant neoplasm to brain
|
28 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 12 | 2006 | 2019 | ||||
Progressive cGVHD
|
40 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 11 | 2009 | 2019 | ||||
Progressive Neoplastic Disease
|
40 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.100 | 1.000 | 11 | 2009 | 2019 | ||||
Neoplasm Metastasis
|
327 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.090 | 1.000 | 9 | 2013 | 2019 | ||||
Metastatic non-small cell lung cancer
|
11 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.070 | 1.000 | 7 | 2014 | 2018 | ||||
CNS metastases
|
14 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.060 | 1.000 | 6 | 2014 | 2020 | ||||
Lung Neoplasms
|
39 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.060 | 0.833 | 6 | 2007 | 2019 | ||||
Metastatic Malignant Neoplasm to the Leptomeninges
|
9 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.060 | 1.000 | 6 | 2013 | 2019 | ||||
HER2 gene amplification
|
14 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.050 | 1.000 | 5 | 2017 | 2019 | ||||
Tumor Progression
|
72 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.040 | 1.000 | 4 | 2016 | 2019 | ||||
Metastatic Lung Adenocarcinoma
|
10 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.030 | 1.000 | 3 | 2011 | 2018 | ||||
Non-small cell lung cancer recurrent
|
4 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.030 | 1.000 | 3 | 2011 | 2016 | ||||
Secondary Neoplasm
|
85 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.030 | 1.000 | 3 | 2014 | 2018 | ||||
Squamous cell carcinoma
|
257 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.030 | 0.667 | 3 | 2011 | 2016 | ||||
Breast Carcinoma
|
2793 | 0.581 | 0.520 | 7 | 55181378 | missense variant | C/T | snv | 2.8E-05 | 5.6E-05 | 0.020 | 1.000 | 2 | 2013 | 2015 |